Latest Headlines

Latest Headlines

Hikma gets large U.S. plant in Boehringer Ingelheim generics deal

Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.

Sawai Pharma ramps up manufacturing in response to Japan's call for more generics

In May, the Japanese government said it would raise its target for the use of generics in public reimbursement to 80% or 90% by 2017--even as it lags an earlier target of 60% this year. That set Japan's Sawai Pharmaceutical into high gear, with the Nikkei Asian Review reporting plans to ramp up generic drug manufacturing capacity by 80% to 18 billion tablets annually by fiscal 2020.

Lupin walks the talk, buys Russian generics maker Biocom

Lupin Pharmaceuticals has made no secret of its intention to grow through acquisitions at home and abroad and last week announced it would make a major buy of Russian generic drug maker ZAO Biocom, placing it in a turbulent but fast-growing market.

Japan aims for high-end drug-device innovation and generics, but will it work?

Japan has ramped up spending on healthcare as part of a broader effort by the government to spur innovation and revive economic fortunes for drug and device makers while at the same time trying to tame costs for reimbursement and hiking sales taxes.

FTC says Teva settlement means pay-for-delay ends, maybe

Teva Pharmaceuticals and the U.S. Federal Trade Commission reached a $1.2 billion settlement that could mean the end of pay-for-delay deals, or not. Asia generics makers selling in the United States are likely to be affected.

Japan eyes higher target for generics despite missing earlier aims

Although it has not even reached its goal of generics comprising 60% of drugs prescribed in Japan, the government is about to raise it to 80% or 90%, according to reports.

Sri Lanka poised to launch mandatory generics-first policy

Sri Lanka's government is expected to move quickly to implement a generics-first drug prescriptions law just passed by the Parliament.

India turns to small manufacturers for state-run generic supply biz

The Indian government has revealed details of its plan to establish itself as a supplier of low-cost, high-quality generic medicines. Instead of relying on the big beasts of Indian generics production, the government is to source its drugs from small and medium-sized players.

InvaGen Pharma and AlphaMed Bottles building new plants on Long Island

Generics drugmaker InvaGen Pharmaceuticals and AlphaMed Bottles, both co-owned companies, said they will build two separate manufacturing facilities in Central Islip, located on Long Island, NY.

Ranbaxy manufacturing mess costs it approvals for Nexium, Valcyte

Ranbaxy said today that the FDA has withdrawn its 6-month exclusivity for Valcyte. It also said it had lost its tentative approval for AstraZeneca's heartburn blockbuster Nexium. Nexium went off patent in May and Valcyte went off patent last year.